Pseudo progression in heterogeneity of right-sided metastatic colon carcinoma during nivolumab therapy: A case report
2019
AbstractRationale:Pseudo progression is a noted phenomenon of immune checkpoint inhibitors therapy, which has been defined as a response after an initial enlargement of the tumor followed by tumor reduction. In July 2017, the Food and Drug Administration granted accelerated approval of nivolumab for
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
20
References
2
Citations
NaN
KQI